Thursday, March 6, 2025 3/6/2025

Bacterial Reprogramming that Contributes to Antibiotic Persistence toward Topoisomerase Inhibitors

Award Number: R01AI167886
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

ABSTRACT Antibiotic treatment failure is one of the greatest global public health challenges of our generation. Antimicrobial- resistant bacteria directly account for over 1.2 million deaths annually worldwide. Microorganisms that are refractory to a new antibiotic often emerge shortly after the drug is introduced in the clinic. Besides becoming heritably resistant to antibiotics, some bacteria in clonal cultures—coined persisters—can reversibly reprogram their phenotypes and become transiently tolerant to a given drug. This can lead to infection relapse after a course of antibiotics, rendering the treatment ineffective. Evidence further suggests that persisters have a higher likelihood of acquiring resistance-conferring mutations. As such, the development of anti-persistence/resistance therapeutic strategies can increase the success of antimicrobial therapy. In this proposal, we focus on antibiotic persistence and resistance development in Escherichia coli and Pseudomonas aeruginosa cells in slow/non-growing cultures, which are less responsive to antibiotics and more difficult to eradicate than their growing counterparts. We aim to discover strategies to potentiate the activity of existing and new topoisomerase inhibitors against these gram-negative pathogens. We recently found that metabolic stimulation and loss of efflux pump action during topoisomerase inhibitor treatment reduce persistence and resistance in non-growing E. coli. To build upon these findings, we will execute the following aims: Aim 1: Discover metabolites that are abundant at infection sites that can modulate persistence and resistance development of E. coli and P. aeruginosa toward first-in-class non-fluoroquinolone topoisomerase inhibitors that are in clinical trials. Aim 2: Investigate the impact of metabolic stimulation and loss of efflux pump action on bacterial metabolism, DNA integrity, and viability during topoisomerase inhibitor treatment. Aim 3: Deduce the effects of metabolic stimulation and loss of efflux pump action during topoisomerase inhibitor treatment on the coordination of molecular events that are important for persister repair and resuscitation after topoisomerase treatment terminates. We envision that the successful completion of this project will expand our knowledge of persister survival strategies and vulnerabilities. This will enable us to develop methods to enhance the activities of existing antibiotics and preserve the efficacy of new drugs in development before their introduction to the clinic.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $489,677 )
2025	2025	UNIVERSITY OF CONNECTICUT HEALTH CENTER	263 FARMINGTON AVE	FARMINGTON	CT	06030	CAPITOL	USA	Allergy and Infectious Diseases Research	000	2	2/28/2025	NON-COMPETING CONTINUATION	$489,677
														Subtotal = $489,677

Issue Date FY: 2024 ( Subtotal = $477,259 )
2024	2024	UNIVERSITY OF CONNECTICUT HEALTH CENTER	263 FARMINGTON AVE	FARMINGTON	CT	06030	CAPITOL	USA	Allergy and Infectious Diseases Research	001	1	5/30/2024	NEW	$47,748
2024	2024	UNIVERSITY OF CONNECTICUT HEALTH CENTER	263 FARMINGTON AVE	FARMINGTON	CT	06030	CAPITOL	USA	Allergy and Infectious Diseases Research	000	1	5/21/2024	NEW	$429,511
														Subtotal = $477,259

Grand Total All Awards = $966,936

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Bacterial Reprogramming that Contributes to Antibiotic Persistence toward Topoisomerase Inhibitors

Award Number: R01AI167886

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer